The Business Research Company’s report on the Amusement Parks Global Market Report 2025 Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the attention deficit hyperactivity disorder (adhd) therapeutics market in recent years?
The increasing prevalence of attention-deficit hyperactivity disorder is expected to propel the growth of the attention-deficit hyperactivity disorder (ADHD) therapeutics market going forward. The rising prevalence of attention-deficit hyperactivity disorder (ADHD) refers to the growing number of individuals diagnosed with this neurodevelopmental disorder over time. ADHS therapeutics address the multifaceted nature of the condition, aiming to improve symptom management, functional impairment, quality of life, and overall well-being for individuals affected by ADHD. For instance, in January 2023, according to reports published by the Guardian, a US-based news publishing company, an estimated 170,000 identified patients were prescribed for ADHD in 2022, a 20.4% increase from the 141,000 identified patients during the same period in 2021. Therefore, the increasing prevalence of ADHD is driving the growth of the attention-deficit hyperactivity disorder (ADHD) therapeutic market.
Access Your Free Sample of the Global Amusement Parks Global Market Report 2025 Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=14042&type=smp
What is the projected market size of the attention deficit hyperactivity disorder (adhd) therapeutics industry, and how is it expected to grow?
The attention deficit hyperactivity disorder (ADHD) therapeutics market size has grown strongly in recent years. It will grow from $13.21 billion in 2024 to $14.1 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to diagnostic awareness and screening programs, rising incidence of ADHD, advancements in treatment modalities, healthcare infrastructure development, and health insurance coverage expansion.
The attention deficit hyperactivity disorder (ADHD) therapeutics market size is expected to see strong growth in the next few years. It will grow to $17.25 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to genetic research and personalized medicine, increasing mental health awareness, global and national mental health initiatives, telehealth expansion, integration of behavioral therapies. Major trends in the forecast period include technological innovations in treatment, research and development initiatives, digital therapeutics integration, precision medicine approaches, innovations in drug delivery systems.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=14042&type=smp
Who are the key players driving competition in the attention deficit hyperactivity disorder (adhd) therapeutics market?
Major companies operating in the attention deficit hyperactivity disorder (ADHD) therapeutics market are Pfizer Inc., Johnson And Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical’s, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., UCB S.A., Amneal Pharmaceuticals LLC, Lupin Ltd., Mallinckrodt Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Purdue Pharma L.P., Arbor Pharmaceuticals LLC, Tris Pharma Inc., NEOS Therapeutic Inc., Concert Pharmaceuticals Inc., Vayarin AG, Rhodes Pharmaceuticals L.P., KemPharm Inc., Impax Laboratories Inc., Aevi Genomic Medicine, Adlon Therapeutics L.P., Ironshore Pharmaceuticals Inc., Highland Therapeutics Inc.
What key trends are expected to drive the assured positioning, navigation, and timing (pnt) market during the forecast period?
Major companies operating in the attention-deficit hyperactivity disorder (ADHD) therapeutics market are focusing on the development of digital advancements such as Endeavor over-the-counter (OTC) versions of digital therapeutics for ADHD to meet increased demand for digital solutions and the rise in demand for remote healthcare. Digital therapeutics are evidence-based therapeutic interventions driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease. These interventions are designed to be used independently or with traditional medical treatments. For instance, in June 2023, Akili, a US-based digital health company, launched an over-the-counter (OTC) version of its video game-based digital therapeutic for adults with attention-deficit hyperactivity disorder (ADHD). The OTC version, EndeavorOTC, is designed to improve attention, time management, and organizational skills. Additionally, this move follows the success of Akili’s FDA-authorized prescription video game treatment, EndeavorRx, for children with ADHD. The OTC version provides adults with a non-drug treatment option for managing ADHD symptoms.
Which key geographies are driving the growth of the attention deficit hyperactivity disorder (adhd) therapeutics market?
North America was the largest region in the attention deficit hyperactivity disorder (ADHD) therapeutic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the attention deficit hyperactivity disorder (ADHD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
What are the key segments driving growth in the attention deficit hyperactivity disorder (adhd) therapeutics market?
The attention deficit hyperactivity disorder (ADHD) therapeutics market covered in this report is segmented –
1) By Drug Type: Stimulants, Non-Stimulants
2) By Psychotherapy: Behavior Therapy, Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Family Therapy
3) By Age Group: Pediatric And Adolescent, Adult
4) By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Retail Pharmacies, E-Commerce
Subsegments:
1) By Stimulants: Amphetamine-Based Stimulants, Methylphenidate-Based Stimulants
2) By Non-Stimulants: Atomoxetine, Guanfacine, Clonidine
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14042
How is the attention deficit hyperactivity disorder (adhd) therapeutics market defined, and what are its core characteristics?
Attention deficit hyperactivity disorder (ADHD) therapeutics refers to the range of treatments and interventions aimed at managing the symptoms and improving the functioning of individuals diagnosed with ADHD. ADHD is a neurodevelopmental disorder characterized by symptoms such as inattention, hyperactivity, and impulsivity that significantly interfere with daily functioning and development. The primary objective of ADHD therapeutics is to enhance attention, impulse control, and overall functioning in daily activities, thereby improving the quality of life for individuals affected by ADHD.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
